Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | KHK | P50053 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734198 | 0.93 | GPR119 (0.59) | GPR119MAPTTP53LRRK2LMNA | |
| SCHEMBL12082170 | 0.84 | GPR119 (0.79) | GPR119MAPTTP53LMNAMEN1 | |
| SCHEMBL30208161 | 0.84 | GPR119 (0.79) | GPR119MAPTTP53LMNAMEN1 | |
| SCHEMBL23711719 | 0.82 | KHK (0.48) | MAPTLMNAKHK | |
| SCHEMBL31280556 | 0.82 | KHK (0.48) | MAPTLMNAKHK | |
| SCHEMBL22581814 | 0.81 | CDK8 (0.55) | GPR119MAPTLRRK2LMNAMEN1 | |
| SCHEMBL23711736 | 0.80 | KHK (0.49) | MAPTLMNAKMT2AKHK | |
| SCHEMBL31279546 | 0.80 | KHK (0.49) | MAPTLMNAKMT2AKHK | |
| SCHEMBL5236610 | 0.80 | GPR119 (0.72) | GPR119MAPTTP53LMNAMEN1 | |
| SCHEMBL23711746 | 0.80 | KHK (0.61) | MAPTTP53LMNAKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | GPR119 11/4885MAPT 2163/4885TP53 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.